Novo Nordisk Says EMA's CHMP Recommends EU Approval Of Haemophilia A Treatment FREHEMGO; Expects First European Launch In Q4 2026

Novo Nordisk announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended EU approval for its haemophilia A treatment, FREHEMGO. The company anticipates the first European launch of the product in the fourth quarter of 2026. FREHEMGO is notable for being the first factor VIIIA mimetic that offers dosing options of once every two weeks and weekly administration via a pre-filled pen.